

# Revathi Kodali, Mpharm, Pharm D

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10637318/publications.pdf>

Version: 2024-02-01

12  
papers

276  
citations

933264

10  
h-index

1199470

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

344  
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>MIDD</sc>0301 â€“ A firstâ€“class antiâ€“inflammatory asthma drug targets <sc>GABA<sub>A</sub></sc> receptors without causing systemic immune suppression. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 75-84.	1.2	10
2	Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles. Molecular Neuropsychiatry, 2019, 5, 84-97.	3.0	54
3	Design and Evaluation of Heterobivalent PAR1â€“PAR2 Ligands as Antagonists of Calcium Mobilization. ACS Medicinal Chemistry Letters, 2019, 10, 121-126.	1.3	10
4	A novel GABA<sub>A</sub> receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L385-L390.	1.3	15
5	Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the Î³-Aminobutyric Acid Type A Receptor (GABA<sub>A</sub>R) Î±6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability. Journal of Medicinal Chemistry, 2018, 61, 2422-2446.	2.9	40
6	A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABA<sub>A</sub> Receptors in the Lung. Molecular Pharmaceutics, 2018, 15, 1766-1777.	2.3	33
7	Synthesis of chiral GABA<sub>A</sub> receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression. Arkivoc, 2018, 2018, 158-182.	0.3	15
8	Attaining in vivo selectivity of positive modulation of Î±3Î±2 GABA<sub>A</sub> receptors in rats: A hard task!. European Neuropsychopharmacology, 2018, 28, 903-914.	0.3	6
9	Pharmacological and antihyperalgesic properties of the novel Î±2/3 preferring GABA A receptor ligand MP-III-024. Brain Research Bulletin, 2017, 131, 62-69.	1.4	23
10	Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABA<sub>A</sub> Receptor Modulators. Molecular Pharmaceutics, 2017, 14, 2088-2098.	2.3	26
11	Optimization of substituted imidazobenzodiazepines as novel asthma treatments. European Journal of Medicinal Chemistry, 2017, 126, 550-560.	2.6	17
12	Development of GABA<sub>A</sub> Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma Treatments. Molecular Pharmaceutics, 2016, 13, 2026-2038.	2.3	27